INNVINNVHealthcare · Medical Care Facilities

INNV Stock Forecast: InnovAge Holding Corp. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$9.08
+0.67% on the day

The 3 Wall Street analysts covering InnovAge Holding Corp. hold a median 12-month price target of $12 — +32.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.2B
Ticker Nerd rank
98 / 100
Median analyst target
$12
Analysts covering
3
Revenue$262.0M+18.3% y/y
Operating income$13.2M
Net income$9.8M
Free cash flow$17.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−15.7%
YTD
+75.0%
1Y
+56.6%
From 52W high
−25.0%
From 52W low
+127.6%
$4
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

INNV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InnovAge Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
91
Accruals
90
Momentum
87
Quality
85
Issuance
85
Revisions
71
Value
66
Volatility
61
Size
41

Growth (91): Sales and profits are climbing, and climbing faster than before.

Volatility (61): The share price moves around a lot.

Size (41): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

INNV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on INNV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26INNVHigh $14Median $12Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
1 Buy1 Hold1 Sell
Low $10Median $12High $14

The green dot is the last close — the median target sits +32.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026KeybancMaintainsOverweight$13 → $14
21 Aug 2026KeybancUpgradeOverweight—
21 Aug 2026KeybancUpgradeOverweight$13
23 Feb 2026JP MorganMaintainsUnderweight$5.00 → $7.00
23 Feb 2026JP MorganMaintainsUnderweight—
18 Sept 2025JP MorganAssumesUnderweight$5.00
17 Dec 2024JP MorganDowngradeUnderweight—
11 Oct 2024KeybancInitiatesSector Weight—
13 Mar 2024JP MorganMaintainsNeutral—
8 Feb 2024Goldman SachsMaintainsNeutral—
15 Feb 2023Goldman SachsMaintainsNeutral—
8 Feb 2023JP MorganMaintainsNeutral—
23 Nov 2022Goldman SachsMaintainsNeutral—
16 Nov 2022CitigroupMaintainsNeutral—
15 Sept 2022BarclaysMaintainsEqual-Weight—
16 May 2022BairdDowngradeNeutral—
11 May 2022Piper SandlerMaintainsUnderweight—
20 Apr 2022Piper SandlerDowngradeUnderweight—
28 Dec 2021Goldman SachsDowngradeNeutral—
27 Dec 2021BarclaysDowngradeEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INNV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

INNV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, InnovAge Holding Corp. returned +56.6% against +17.5% for the S&P 500, dividends included.

INNV vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Jan 26Apr 26Jul 26Oct 26INNVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

INNV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+18.4%
Analysts raising
1
Analysts cutting
0
Fundamentals

InnovAge Holding Corp. (INNV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
162.4×

Cheaper than 4% of US stocks

Price / sales
1.2×

Cheaper than 64% of US stocks

Price / book
5.2×

Cheaper than 18% of US stocks

EV / EBITDA
44.9×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
18.3%

Higher than 67% of US stocks

Earnings growth (YoY)
18.3%

Higher than 57% of US stocks

Gross margin
23.9%

Higher than 26% of US stocks

Operating margin
5.0%

Higher than 55% of US stocks

Net margin
−0.3%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−0.3%

Higher than 44% of US stocks

Return on assets
0.7%

Higher than 47% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

InnovAge Holding Corp. (INNV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • InnovAge Holding Corp. has a market value of $1.2B and an enterprise value of $1.2B.

  • Revenue in the twelve months to 30 June 2026: $989.7M. The latest quarter grew 18.3% year on year.

  • Net income over the same four quarters: −$683K, a −0.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.02.

  • Free cash flow in the twelve months to 30 June 2026: $50.4M.

  • InnovAge Holding Corp. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 136.0M.

  • Trailing P/E: 162.4×; forward P/E: 18.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • InnovAge Holding Corp. employs 2,500 people — $396K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

INNV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
INNVInnovAge Holding Corp.$1.2B
98
USPHU.S. Physical Therapy, Inc.$1.3B
57
NUTXNutex Health, Inc.$1.4B
88
PNTGThe Pennant Group, Inc.$1.4B
72
AGLAgilon Health, Inc.$1.5B
70
AMNAMN Healthcare Services, Inc.$1.5B
100
HCSGHealthcare Services Group, Inc.$1.5B
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InnovAge Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest INNV news & analysis

InnovAge: Care Economics Should Keep Improving Going Forward

Seeking Alpha · 26 Sept 2026neutral

Seeking Alpha discusses InnovAge's strategy of filling existing centers and controlling care costs, which could convert continued enrollment growth into faster earnings growth in the long run. The piece notes that an operating recovery may make the current stock price attractive in hindsight, but slower reimbursement growth in coming quarters underscores the need for good execution.

Why it matters — A InnovAge shareholder would care because the analysis weighs the potential for faster earnings growth from its operational strategy against headwinds from slower reimbursement growth.

InnovAge Announces Pricing of Secondary Offering of Common Stock by Selling Stockholders

GlobeNewsWire · 23 Sept 2026neutral

InnovAge Holding Corp. announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock by selling stockholders—investment funds affiliated with Apax Partners and Welsh, Carson, Anderson & Stowe—at $9.25 per share, dated Sept. 22, 2026.

Why it matters — INNV watchers would care because this secondary offering involves major existing shareholders selling a significant block of stock, potentially affecting share supply and ownership structure.

InnovAge Announces Launch of Proposed Secondary Offering of Common Stock by Selling Stockholders

GlobeNewsWire · 22 Sept 2026neutral

InnovAge Holding Corp. announced the launch of an underwritten public offering of its common stock by investment funds affiliated with Apax Partners and Welsh, Carson, Anderson & Stowe, who are acting as selling stockholders. The offering covers shares held by these selling stockholders in the Denver-based PACE provider.

Why it matters — The secondary offering by major affiliated investors could affect the supply of InnovAge shares in the market and reflects these stockholders' decision to sell their positions.

InnovAge: Operational Momentum Is Winning Out Over The Risks

Seeking Alpha · 10 Sept 2026positive

InnovAge Holding Corp. is described as remaining a Buy as profitability and cash flow have improved despite shares rising over 30%. Fiscal 2026 revenue grew 15.9% to $989.7M with adjusted EBITDA margin expanding to 9.6%, and management forecasts 2027 revenue of $1.05–$1.085B and adjusted EBITDA of $105–$115M while prioritizing capacity utilization over aggressive new builds.

Why it matters — The report highlights improving profitability, cash generation, and upgraded guidance for InnovAge watchers, framing operational momentum as outweighing the company's perceived risks.

InnovAge Holding Corp. (INNV) Q4 2026 Earnings Call Transcript

Seeking Alpha · 9 Sept 2026neutral

The item is a Seeking Alpha transcript of InnovAge Holding Corp.'s Q4 2026 earnings call, presenting the company's discussion of its latest quarterly financial results and performance.

Why it matters — The transcript provides InnovAge watchers with direct insight into the company's Q4 2026 results and management commentary.

FAQ

Frequently asked questions about INNV stock

What is the INNV stock price forecast for 2026-2027?

The 3 Wall Street analysts covering InnovAge Holding Corp. have a median 12-month price target of $12, with estimates ranging from $10 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is INNV stock a buy right now?

Of the 3 analysts covering InnovAge Holding Corp., 1 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks InnovAge Holding Corp. 98 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank INNV?

As at 14 Oct 2026, InnovAge Holding Corp. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (91 of 100).

Will INNV stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +32.2% from the last close, and Ticker Nerd's factor model ranks InnovAge Holding Corp. 98 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the INNV stock forecast for 2030?

No analyst covering InnovAge Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INNV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $14 over the next 12 months.

How has INNV stock performed over the past year?

InnovAge Holding Corp. returned +56.6% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InnovAge Holding Corp. do?

InnovAge Holding Corp. is a healthcare services company focused on managing the care of frail, high-cost seniors, particularly those who are eligible for both Medicare and Medicaid.

What is the latest news on INNV?

The most recent item we track (Seeking Alpha, 26 Sept 2026): "InnovAge: Care Economics Should Keep Improving Going Forward". Seeking Alpha discusses InnovAge's strategy of filling existing centers and controlling care costs, which could convert continued enrollment growth into faster earnings growth in the long run. The piece notes that an operating recovery may make the current stock price attractive in hindsight, but slower reimbursement growth in coming quarters underscores the need for good execution.

Company

About InnovAge Holding Corp.

InnovAge Holding Corp. is a healthcare services company focused on managing the care of frail, high-cost seniors, particularly those who are eligible for both Medicare and Medicaid. Through its Program of All-inclusive Care for the Elderly (PACE) model, the company provides coordinated medical and support services designed to help older adults remain in their homes and communities for as long as possible. Its offerings include primary and specialty care delivered at centers, in-home assistance, therapy services, dental and mental health care, meals, transportation, and ongoing care management. InnovAge Holding Corp. serves a participant-centered role in senior healthcare by integrating clinical, social, and day-to-day support services under one care framework. Headquartered in Denver, Colorado, the company operates as a significant provider in the U.S. senior care market.

CEO Mr. Patrick Blair · 2,500 employees · United States · https://www.innovage.com